Journal of cancer science and clinical therapeutics最新文献_第5页

Rapidly Progressive Paraneoplastic Neuropathy Associated with Renal Cell Carcinoma: A Case Report. 快速进展的副肿瘤神经病变伴肾细胞癌1例报告。

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079171

Divya Shah, Jaya Trivedi, Steven Vernino, Shaida Khan

{"title":"Rapidly Progressive Paraneoplastic Neuropathy Associated with Renal Cell Carcinoma: A Case Report.","authors":"Divya Shah, Jaya Trivedi, Steven Vernino, Shaida Khan","doi":"10.26502/jcsct.5079171","DOIUrl":"https://doi.org/10.26502/jcsct.5079171","url":null,"abstract":"Background: Paraneoplastic neurological disorders are rare syndromes that occur with various malignancies including renal cell carcinoma. Symptoms of paraneoplastic neurological disorders are diverse and involve either the central nervous system, peripheral nervous system, or both.Case presentation: We present a patient with diffuse limb pain, rapidly progressive asymmetric motor and sensory symptoms and distal upper limb atrophy. Electrodiagnostic testing was suggestive of mononeuritis multiplex. Initial empiric treatment with corticosteroids did not lead to improvement. Further diagnostic studies revealed bilateral clear cell renal carcinoma. Treatment with plasmapheresis led to significant and rapid improvement in pain and limb strength.Conclusions: This case highlights the rare occurrence of paraneoplastic neuropathy in renal cancer and emphasizes the importance of screening for malignancy in patients presenting with rapidly progressive multifocal neuropathy.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"6 3","pages":"333-335"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9851384/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10627591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Forward Variable Selection Improves the Power of Random Forest for High-Dimensional Micro Biome Data 前向变量选择提高了随机森林对高维微生物群数据的处理能力

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079147

Tung Dang, H. Kishino

{"title":"Forward Variable Selection Improves the Power of Random Forest for High-Dimensional Micro Biome Data","authors":"Tung Dang, H. Kishino","doi":"10.26502/jcsct.5079147","DOIUrl":"https://doi.org/10.26502/jcsct.5079147","url":null,"abstract":"Random forest (RF) captures complex feature patterns that differentiate groups of samples and is rapidly being adopted in microbiome studies. However, a major challenge is the high dimensionality of microbiome datasets. They include thousands of species or molecular functions of particular biological interest. This high dimensionality significantly reduces the power of random forest approaches for identifying true differences and functional characterization. The widely used Boruta algorithm iteratively removes features that are proved by a statistical test to be less relevant than random probes. We developed a massively parallel forward variable selection algorithm and coupled it with the RF classifier to maximize the predictive performance. The forward variable selection algorithm adds new variable to a set of selected variables as far as the prespecified criterion of predictive power is improved. At each step, the parameters of random forest are optimized. We demonstrated the performance of the proposed approach, which we named RF-FVS, by analyzing two published datasets from large-scale case-control studies: (i) 16S rRNA gene amplicon data for Clostridioides Difficile Infection (CDI) and (ii) shotgun metagenomics data for human colorectal cancer (CRC). The RF-FVS approach further screened the variables that the Boruta algorithm left J Cancer Sci Clin Ther 2022; 6 (1): 87-105 DOI: 10.26502/jcsct.5079147 Journal of Cancer Science and Clinical Therapeutics 88 and improved the accuracy of the random forest classifier from 81% to 99.01% for CDI and from 75.14% to 90.17% for CRC. Valid variable selection is essential for the analysis of high-dimensional microbiota data. By adopting the Boruta algorithm for pre-screening of the variables, our proposed RF-FVS approach improves the accuracy of random forest significantly with minimum increase of computational burden. The procedure can be used to identify the functional profiles that differentiate samples between different conditions.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Chronic Myelomonocytic Leukemia (CMML): A systematic Review of Literature and Update 慢性髓单细胞白血病(CMML):文献综述和最新进展

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079150

A. Blackmon, I. Amanam, Monzr M. Al Malki, H. Ali, S. Otoukesh

引用次数: 0

Respiratory Viral Infections in Cancer Patients: Epidemiological, Clinical and Cost-Effectiveness study from a Developing Country 癌症患者的呼吸道病毒感染:来自一个发展中国家的流行病学、临床和成本效益研究

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079166

N. Bansal, N. Sachdeva, D. Bhurani, G. Kapoor, Pinky Yadav, S. Goyal, V. Talwar, U. Batra

{"title":"Respiratory Viral Infections in Cancer Patients: Epidemiological, Clinical and Cost-Effectiveness study from a Developing Country","authors":"N. Bansal, N. Sachdeva, D. Bhurani, G. Kapoor, Pinky Yadav, S. Goyal, V. Talwar, U. Batra","doi":"10.26502/jcsct.5079166","DOIUrl":"https://doi.org/10.26502/jcsct.5079166","url":null,"abstract":"Background: Diagnosis of respiratory viral pathogens can lead to therapeutic changes, improvement in infection control practices and reduction in use of antibiotics. Methods: This is a retrospective study which looked into the case records of patients (June 2020-Dec 2021) who were diagnosed with a respiratory viral infection. Demographic, clinical and antibiotic prescription patterns of these patients were studied. Inter-group analysis was done between antibiotic de-escalation cohort and non-descalation cohort. Results: Total of 57 patients were identified with median age of 40 years (range: 3-68). Hematological malignancies were present in 45 (78.9%) of patients, whereas 14 (24.5%) patients were stem cell transplant recipients. Severe neutropenia was seen in 32 (56.1%) patients with median duration of neutropenia of 7 (range 5-20) days. RSV (36.8%) was the most common virus detected. Antibiotic de-escalation was done in 33 (57.8%) of patients and in 13 (22.8%) bacterial co-infection was diagnosed. More than 3/4 th patients were shifted to isolation and nearly 9000 INR per patient were saved by de-escalation of antibiotics. On inter-group analysis, non-de-escalation cohort had longer length of stay (10 vs 3 days; p =0.005), no antibiotic cost reduction (0 vs 9620; p=0.0003), higher mortality (16.6% vs 0%; p =0.01) & higher rhinovirus detection rates (41.6% vs 3%; p=0.0002). Conclusion: Diagnosis of respiratory viral infection helped in improving antibiotic stewardship and infection control practices.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HPV16-Positive Skin Metastasis at the Nose 5 Years Following Treatment of an HPV16-Positive Squamous Cell Carcinoma of the Tonsil – A Case Report and Review of Literature hpv16阳性扁桃体鳞状细胞癌治疗5年后鼻部皮肤转移1例报告及文献复习

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079173

Christiane Stuhlmann-Leisz, A. Fazel, Lukas Lükewille, C. Röcken, M. Laudien, Elgar Susanne Quabius, M. Hoffmann

{"title":"HPV16-Positive Skin Metastasis at the Nose 5 Years Following Treatment of an HPV16-Positive Squamous Cell Carcinoma of the Tonsil – A Case Report and Review of Literature","authors":"Christiane Stuhlmann-Leisz, A. Fazel, Lukas Lükewille, C. Röcken, M. Laudien, Elgar Susanne Quabius, M. Hoffmann","doi":"10.26502/jcsct.5079173","DOIUrl":"https://doi.org/10.26502/jcsct.5079173","url":null,"abstract":"This case report presents the disease course of a patient who developed HPV16-positive skin metastasis to the nose of HPV16-positive tonsillar carcinoma treated 5 years previously. The report critically reviews the available literature, particularly the comparable case reports available to date. In light of conflicting findings, it now appears unclear whether the occurrence of skin metastases reflecting an unusual pattern of metastasis is more typical of the course of HPV-positive HN/OSCC. There are reports suggesting this association, including our case report. On the other hand, there are retrospective study results that rather do not point to an association of skin metastases explicitly with (HPV-positive) OSCC. Rather, it must be critically questioned whether there is indeed a significant association between a specific metastatic pattern including unusual metastatic sites such as the skin, or whether merely increased attention to HPV-positive cancers leads to a higher publication rate of these cases. Extensive epidemiologic evidence should be obtained on a retrospective and prospective basis before recommendations for surveillance of corresponding patients are derived from the assumption of an atypical or different metastatic pattern in HPV-positive HNSCC.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn? Covid-19疫情对淋巴瘤患者的影响:我们学到了什么?

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079161

Piero Maria Stefani, F. Cinetto, R. Scarpa, E. Mauro, C. Agostini, M. Rattazzi

{"title":"The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn?","authors":"Piero Maria Stefani, F. Cinetto, R. Scarpa, E. Mauro, C. Agostini, M. Rattazzi","doi":"10.26502/jcsct.5079161","DOIUrl":"https://doi.org/10.26502/jcsct.5079161","url":null,"abstract":"The Impact of Covid-19 Outbreak among Lymphoma Patients: What Did We Learn? Journal Clinical Therapeutics (2022): Abstract A very high number of articles have been published regarding SARSCOVID-19 infection among oncohematology patients. However, outside epidemiologic data and guidelines regarding the management of SARSCOVID-19 disease, no shared recommendations or expert opinions are available to decide whether it is advisable to initiate antineoplastic therapy during a phase of pandemic and, if so, how to modulate the treatment schedule. The need to administer antineoplastic or biological drugs and available monoclonal antibodies licensed for lymphoproliferative diseases makes it particularly complex in this perspective to define reasoned, evidence-based choices. We reviewed published studies with the largest cohort of patients, intending to recognize the most relevant risk factors. We have highlighted some unresolved questions about immunologic perturbation during SARSCOVID-19 infection that hinder a defined and biologically oriented approach, especially in the case of immunosuppression, both primary and acquired. It is interesting, in this context, that preliminary evidence shows a characteristic clinical course of SARSCOVID-19 infection that suggests specific management. We also summarized the role of immunoglobulin replacement treatment or monoclonal antibody administration.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective Prevention and Effective Treatment Oncological Diseases with Methods Resonance Destruction and Resonance of Creation 共振破坏和共振创造方法有效预防和治疗肿瘤疾病

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079152

Praznikov Viktor

{"title":"Effective Prevention and Effective Treatment Oncological Diseases with Methods Resonance Destruction and Resonance of Creation","authors":"Praznikov Viktor","doi":"10.26502/jcsct.5079152","DOIUrl":"https://doi.org/10.26502/jcsct.5079152","url":null,"abstract":"1. Literature Review In our previous work (Praznikov V. \"Resonant Medicine\" \"International Journal of Medical Science and Clinical Invention\". 9 (2), p. 5962-5973, 2022 [1] and in monographs [2-7] considered two options for using resonance in medicine the resonance of destruction and the resonance of creation. Resonance has been used for many years in the treatment of various diseases [1-7, 11]. In this paper, we will consider the possibilities of effective treatment and effective prevention of oncological diseases using the methods of resonance of destruction and resonance of creation. For the diagnosis and treatment of diseases, bioresonance therapy is used, which arose thanks to the German researchers R. Fol, F. Werner [12], Shimmel H.W. [13]. In the diagnosis and treatment of bioresonance therapy, the so-called \"nosodes\" are used wave copies of various diseases, including oncological ones, and \"organ preparations\" wave copies of normally functioning organs. A feature of the use of nosodes and organ preparations in our work was that we used not only low potencies of nosodes and organ preparations, but also high ones [1-7], while in previous works we used only low potencies of nosodes and organ preparations [8-11].","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

A Female Pediatric Patient with Bilateral Ovarian Cysts Presenting to Gynecologic Oncology Diagnosed as Van Wyk-Grumbach Syndrome: A Case Report 女儿童双侧卵巢囊肿呈现妇科肿瘤诊断为Van Wyk-Grumbach综合征:1例报告

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079170

Bayley Richardson, Archana Ayyar, Leigh Hickham, Chinnadurai Mani, Komaraiah Palle, Mark Reedy

{"title":"A Female Pediatric Patient with Bilateral Ovarian Cysts Presenting to Gynecologic Oncology Diagnosed as Van Wyk-Grumbach Syndrome: A Case Report","authors":"Bayley Richardson, Archana Ayyar, Leigh Hickham, Chinnadurai Mani, Komaraiah Palle, Mark Reedy","doi":"10.26502/jcsct.5079170","DOIUrl":"https://doi.org/10.26502/jcsct.5079170","url":null,"abstract":"We describe a case of a 7-year-old female who presented to the emergency department (ED) with a three-day history of vaginal bleeding, progressive abdominal pain, and dehydration. Initial computerized tomography (CT) scan of the abdomen followed by a transabdominal ultra-sound of the pelvis identified bilateral, symmetric adnexal cysts and proliferative-phase endometrium with no evidence of inflammatory or malignancy-related findings. A gynecologic oncology consult led to surgical exploration diagnosing the child with an acute surgical abdomen. Surgery was performed through a vertical infra-umbilical, mini-laparotomy (4 cm) incision. Both intra-operative and final pathology confirmed bilateral ovarian, low malignant potential (LMP), granulosa cell tumors. Postoperative bone age was over 18 months less than the patient’s age. The discrepant bone age prompted investigation into pediatric syndromes characterized by juvenile hypothyroidism, isosexual precocious puberty, and granulosa cell tumors with delayed bone age. A rare diagnosis matching all criteria was identified as Van Wyk-Grumbach Syndrome (VW-GS). This syndrome was originally reported in 1960 by Drs. Van Wyk and Grumbach. They identified the discrepancies in bone age and how simple thyroid replacement results in complete resolution of this unique syndrome. Our literature review found few reports related to VW-GS in the gynecologic oncology case studies. We hope this report will further assist in the appropriate diagnosis and management of similar cases to avoid unnecessary and invasive interventions and treatment.","PeriodicalId":73634,"journal":{"name":"Journal of cancer science and clinical therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69348774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hereditary Risk Assessment for BRCA Breast and/or Ovarian Cancer BRCA乳腺癌和/或卵巢癌遗传风险评估

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079162

M. T. Martínez, M. Tapia, Lina Candia, B. Bermejo, I. Garrido-Cano, A. Adam-Artigues, P. Eroles, A. Lluch, I. de Juan, E. Contel, C. Hernando, Sara S Oltra, Juan M. Cejalvo, I. Chirivella

引用次数: 0

Efficacy and Safety of Zanubrutinib in IgA-secerning Lymphoplasmacytic Lymphoma 扎鲁替尼治疗iga筛选淋巴浆细胞性淋巴瘤的疗效和安全性

Journal of cancer science and clinical therapeutics Pub Date : 2022-01-01 DOI: 10.26502/jcsct.5079151

G. Zamprogna, Anna Maria Frustaci, M. Deodato, H. Allewelt, D. Weber, C. Rigamonti, A. Tedeschi

引用次数: 0